Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 60

Sort by

Sort Order Select

Journal Articles

Crowdsourced High-Risk Classifiers for Multiple Myeloma Patients Commonly Identify PHF19 As a Robust Progression Biomarker

Blood (2019) 134 (Supplement_1): 4370.

https://doi.org/10.1182/blood-2019-127362

Published: 2019

Journal Articles

Re-Constructing and Exploiting Transcriptional Regulatory Networks in Multiple Myeloma Drug Resistance

Rafael Renatino-Canevarolo, PhD, Praneeth Reddy Sudalagunta, PhD, Maria D Coelho Siqueira Silva, MSc, Mark B. Meads, PhD, Alexandre Tungesvik, MD, Gabriel De Avila, Alugubelli Raghunandan Reddy, Minerva Nong, Jamie Teer, PhD, Eric A. Welsh, PhD, Tint Lwin, MD PhD, Amit Kulkarni, PhD, Hongyue Dai, PhD, William S. Dalton, PhDMD, Kenneth H. Shain, MD PhD, Ariosto Siqueira Silva, PhD

Blood (2019) 134 (Supplement_1): 5544.

https://doi.org/10.1182/blood-2019-128442

Published: 2019

Journal Articles

Reinforcement Learning to Optimize the Treatment of Multiple Myeloma

Kenneth H. Shain, MD PhD, Daniel Hart, Ariosto Siqueira Silva, PhD, Raghunandanreddy Alugubelli, MS, Gabriel De Avila, BS, Praneeth Reddy Sudalagunta, PhD, Alexandre Tungesvik, MD, Amit Kulkarni, PhD, Carmelo Blancuicett, PhD MD, Hongyue Dai, PhD, Taiga Nishihori, MD, Jason B. Brayer, PhDMD, Brandon Blue, MD, Melissa Alsina, MD, Rachid Baz, MD, William S. Dalton, PhDMD

Blood (2019) 134 (Supplement_1): 5511.

https://doi.org/10.1182/blood-2019-132234

Published: 2019

Journal Articles

Pharmacoproteomics Identifies PLK1 As Vulnerability for Aggressive B-Cell Lymphomas

Blood (2018) 132 (Supplement 1): 2853.

https://doi.org/10.1182/blood-2018-99-118004

Published: 2018

Journal Articles

A Systems Biology Approach to Identify Mechanisms of Therapy Resistance in Multiple Myeloma

Rafael Renatino Canevarolo, PhD, Praneeth Reddy Sudalagunta, PhD, Maria D Coelho Siqueira Silva, MSc, Mark B. Meads, PhD, Priscilla Granados, Anders Berglund, Amit Kulkarni, PhD, Hongyue Dai, PhD, William S. Dalton, PhDMD, Ion Petre, PhD, Kenneth H. Shain, MD PhD, Ariosto Siqueira Silva, PhD

Blood (2018) 132 (Supplement 1): 3266.

https://doi.org/10.1182/blood-2018-99-118784

Published: 2018

Journal Articles

Systems Biology Analysis Identifies Targetable Vulnerability Networks to Proteasome Inhibitors in Multiple Myeloma

Mark B. Meads, PhD, Rafael Renatino Canevarolo, PhD, Praneeth Reddy Sudalagunta, PhD, Paula S. Oliveira, Dario M. Magaletti, Bin Fang, PhD, Maria D Coelho Siqueira Silva, MSc, Amit Kulkarni, PhD, Hongyue Dai, PhD, William S. Dalton, PhDMD, Ion Petre, PhD, John M. Koomen, PhD, Ariosto Siqueira Silva, PhD, Kenneth H. Shain, MD PhD

Blood (2018) 132 (Supplement 1): 950.

https://doi.org/10.1182/blood-2018-99-120269

Published: 2018

Journal Articles

Crowdsourcing a High-Risk Classifier for Multiple Myeloma Patients

Blood (2017) 130 (Supplement 1): 265.

https://doi.org/10.1182/blood.V130.Suppl_1.265.265

Published: 2017

Journal Articles

The Synergistic Effect of Melphalan and XPO1 Inhibition in Pre-Clinical Models of Multiple Myeloma

Yan Cui, MD, Joel G Turner, PhD, Jana L Dawson, BS, Juan A Gomez, BS, Kenneth H. Shain, MD PhD, Mark B Meads, PhD, Erkan Baloglu, PhD, William S. Dalton, PhD MD, Taiga Nishihori, MD, Daniel M Sullivan, MD

Blood (2016) 128 (22): 5662.

https://doi.org/10.1182/blood.V128.22.5662.5662

Published: 2016

Journal Articles

Next Generation XPO1 Inhibitor KPT-8602 for the Treatment of Drug-Resistant Multiple Myeloma

Joel G Turner, PhD, Jana L Dawson, BS, Christopher L Cubitt, PhD, Erkan Baluglo, PhD, Steven Grant, MD, Yun Dai, PhD, Kenneth H Shain, MD PhD, William S. Dalton, PhD MD, Sharon Shacham, William Senapedis, PhD, Daniel M Sullivan, MD

Blood (2015) 126 (23): 1818.

https://doi.org/10.1182/blood.V126.23.1818.1818

Published: 2015

Journal Articles

Silencing c-Myc Using Myc Inhibitor JQ1 and EZH2 Inhibitor DZNep Blocks Converging Survival Signals in Aggressive B-Cell Lymphomas

Xiaohong Zhao, PhD, Tint Lwin, MD, PhD, Xinwei Zhang, MD, Andy Huang, Jian Wang, Victor E. Marquez, PhD, Selina Chen-Kiang, PhD, James E Bradner, MD, William S. Dalton, PhD, MD, Eduardo M. Sotomayor, MD, Jianguo Tao, MD, PhD

Blood (2012) 120 (21): 4618.

https://doi.org/10.1182/blood.V120.21.4618.4618

Published: 2012

Journal Articles

Targeting Mir-548m-HDAC6 Axis Circumvents Stroma- Mediated Drug Resistance (CAM-DR) and Clonogenicity in Non-Hodgkin B-Cell Lymphomas

Tint Lwin, MD, PhD, Xiaohong Zhao, PhD, Fengdong Cheng, MD, Xinwei Zhang, MD, Yizhuo Zhang, Andy Huang, Lynn Moscinski, MD, William S. Dalton, PhD, MD, Eduardo M. Sotomayor, MD, Jianguo Tao, MD, PhD

Blood (2012) 120 (21): 5094.

https://doi.org/10.1182/blood.V120.21.5094.5094

Published: 2012

Journal Articles

B Cell Receptor (BCR) Signal Pathways Confer Microenvironment-Mediated Drug Resistance and Are Promising Therapeutic Targets for B Cell Lymphomas

Jiangchuan Tao, Tint Lwin, MD, PhD, Xiaohong Zhao, PhD, Ling Zhang, MD, Lynn Moscinski, MD, Eduardo M. Sotomayor, MD, William S. Dalton, PhD, MD, Jianguo Tao, MD, PhD

Blood (2012) 120 (21): 4918.

https://doi.org/10.1182/blood.V120.21.4918.4918

Published: 2012

Journal Articles

Pyk2 Mediates Enhanced STAT3 Phosphorylation Following Collaborative Signaling Between gp130 and beta1 Integrins in Adhered Myeloma and B Cells

Mark B Meads, Ph.D., Liang Nong, M.D., Linda Mathews, William S. Dalton, PhD, MD, Kenneth H. Shain, MD, PhD

Blood (2011) 118 (21): 2895.

https://doi.org/10.1182/blood.V118.21.2895.2895

Published: 2011

Journal Articles

Outcomes Analysis of Doublets of Novel Agents with Corticosteroids Versus Regimens with 3 or More Agents for Multiple Myeloma (MM): A Retrospective Analysis

Rachid Baz, MD, Amila M Patel, PharmD, Viet Q. Ho, PharmD, BCOP, Kenneth Shain, MD, PhD, Melissa Alsina, MD, Taiga Nishihori, MD, Jose Leonel Ochoa-Bayona, M.D., Daniel Sullivan, MD, Benjamin Djulbegovic, MD, PhD, William S. Dalton, PhD, MD

Blood (2011) 118 (21): 1878.

https://doi.org/10.1182/blood.V118.21.1878.1878

Published: 2011

Journal Articles

Follicular dendritic cell–dependent drug resistance of non-Hodgkin lymphoma involves cell adhesion–mediated Bim down-regulation through induction of microRNA-181a

Tint Lwin, Jianhong Lin, Yong Sung Choi, Xinwei Zhang, Lynn C. Moscinski, Kenneth L. Wright, Eduardo M. Sotomayor, William S. Dalton, Jianguo Tao

Blood (2010) 116 (24): 5228–5236.

https://doi.org/10.1182/blood-2010-03-275925

Published: 2010

Includes: Supplemental data

Journal Articles

Characterization of Clonal Pre-B Cell Progenitors of Plasma Cells In Multiple Myeloma

Lia Perez, MD, Kelly Boucher, BA, Nancy Parquet, BS, Melissa Alsina, MD, Rachid Baz, MD, Claudio Anasetti, MD, William S. Dalton, PhD, MD

Blood (2010) 116 (21): 1921.

https://doi.org/10.1182/blood.V116.21.1921.1921

Published: 2010

Journal Articles

Selected Resistance to Topoisomerase II Inhibitors Correlates with the Over Expression of FANCF In a Fanconi Anemia/BRCA DNA Repair Pathway Independent Manner.

Kenneth H. Shain, MD, PhD, Liang Nong, M.D., Danielle Yarde, Vasco Oliveira, William S. Dalton, PhD, MD

Blood (2010) 116 (21): 3372.

https://doi.org/10.1182/blood.V116.21.3372.3372

Published: 2010

Journal Articles

Microenvironment-Mediated Regulation of Micrornas In B-Lymphocytes as a Novel Mechanism for Terminal B-Cell Differentiation and Lymphomagenesis.

Jianhong Lin, M.D, Tint Lwin, MD, PhD, Wayne Tam, MD, PhD, Jian-Jun Zhao, Luis Crespo, Yong Sung Choi, Xinwei Zhang, Victoria Tannenbaum, Eduardo M. Sotomayor, MD, Lynn C. Moscinski, MD, William S. Dalton, PhD, MD, Ken Wright, PhD, Jianguo Tao, MD, PhD

Blood (2010) 116 (21): 3853.

https://doi.org/10.1182/blood.V116.21.3853.3853

Published: 2010

Journal Articles

Treatments and Outcomes of Patients with Multiple Myeloma (MM) Older Than 75 Years of Age: A Single Institution Experience

Elizabeth Finley-Oliver, RN, Kenneth Shain, MD, PhD, Taiga Nishihori, MD, Jose-Leonel Ochoa-Bayona, M.D., Melissa Alsina, MD, Daniel Sullivan, MD, William S. Dalton, PhD, MD, Rachid Baz, MD

Blood (2010) 116 (21): 4756.

https://doi.org/10.1182/blood.V116.21.4756.4756

Published: 2010

Journal Articles

Updated Results of the Phase II Study of Pegylated Liposomal Doxorubicin (PLD), Low Dose Dexamethasone (DEX) and Lenalidomide (LEN) In Patients with Newly Diagnosed (ND) Multiple Myeloma (MM)

Rachid Baz, MD, Mohamad A Hussein, MD, Daniel Sullivan, MD, Jose-Leonel Ochoa-Bayona, M.D., Monique A Hartley, MD, Kenneth Shain, MD, PhD, Taiga Nishihori, MD, Jennifer Paleveda, Kara Kosakowski, William S. Dalton, PhD, MD, Melissa Alsina, MD

Blood (2010) 116 (21): 3054.

https://doi.org/10.1182/blood.V116.21.3054.3054

Published: 2010

NARROW

Crowdsourced High-Risk Classifiers for Multiple Myeloma Patients Commonly Identify PHF19 As a Robust Progression Biomarker

Re-Constructing and Exploiting Transcriptional Regulatory Networks in Multiple Myeloma Drug Resistance

Reinforcement Learning to Optimize the Treatment of Multiple Myeloma

Pharmacoproteomics Identifies PLK1 As Vulnerability for Aggressive B-Cell Lymphomas

A Systems Biology Approach to Identify Mechanisms of Therapy Resistance in Multiple Myeloma

Systems Biology Analysis Identifies Targetable Vulnerability Networks to Proteasome Inhibitors in Multiple Myeloma

Crowdsourcing a High-Risk Classifier for Multiple Myeloma Patients

The Synergistic Effect of Melphalan and XPO1 Inhibition in Pre-Clinical Models of Multiple Myeloma

Next Generation XPO1 Inhibitor KPT-8602 for the Treatment of Drug-Resistant Multiple Myeloma

Silencing c-Myc Using Myc Inhibitor JQ1 and EZH2 Inhibitor DZNep Blocks Converging Survival Signals in Aggressive B-Cell Lymphomas

Targeting Mir-548m-HDAC6 Axis Circumvents Stroma- Mediated Drug Resistance (CAM-DR) and Clonogenicity in Non-Hodgkin B-Cell Lymphomas

B Cell Receptor (BCR) Signal Pathways Confer Microenvironment-Mediated Drug Resistance and Are Promising Therapeutic Targets for B Cell Lymphomas

Pyk2 Mediates Enhanced STAT3 Phosphorylation Following Collaborative Signaling Between gp130 and beta1 Integrins in Adhered Myeloma and B Cells

Outcomes Analysis of Doublets of Novel Agents with Corticosteroids Versus Regimens with 3 or More Agents for Multiple Myeloma (MM): A Retrospective Analysis

Follicular dendritic cell–dependent drug resistance of non-Hodgkin lymphoma involves cell adhesion–mediated Bim down-regulation through induction of microRNA-181a

Characterization of Clonal Pre-B Cell Progenitors of Plasma Cells In Multiple Myeloma

Selected Resistance to Topoisomerase II Inhibitors Correlates with the Over Expression of FANCF In a Fanconi Anemia/BRCA DNA Repair Pathway Independent Manner.

Microenvironment-Mediated Regulation of Micrornas In B-Lymphocytes as a Novel Mechanism for Terminal B-Cell Differentiation and Lymphomagenesis.

Treatments and Outcomes of Patients with Multiple Myeloma (MM) Older Than 75 Years of Age: A Single Institution Experience

Updated Results of the Phase II Study of Pegylated Liposomal Doxorubicin (PLD), Low Dose Dexamethasone (DEX) and Lenalidomide (LEN) In Patients with Newly Diagnosed (ND) Multiple Myeloma (MM)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only